Publications

Detailed Information

Feasibility of a slower lamotrigine titration schedule for bipolar depression: a naturalistic study

DC Field Value Language
dc.contributor.authorJoe, Soo Hyun-
dc.contributor.authorChang, Jae Seung-
dc.contributor.authorWon, Seunghee-
dc.contributor.authorRim, Hyo-Deog-
dc.contributor.authorHa, Kyooseob-
dc.contributor.authorHa, Tae Hyon-
dc.date.accessioned2012-07-05T01:40:02Z-
dc.date.available2012-07-05T01:40:02Z-
dc.date.issued2009-03-
dc.identifier.citationINTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY; Vol.24(2); 105-110ko_KR
dc.identifier.issn0268-1315-
dc.identifier.urihttps://hdl.handle.net/10371/78547-
dc.description.abstractThe development of a skin rash is often associated with a rapid escalation of lamotrigine dose. We used lamotrigine to treat 259 patients with Diagnostic and Statistical Manual of Mental Disorders, 4th edition, bipolar depression using either the standard titration schedule (n=132) or a slower titration schedule (n=127) and compared the clinical efficacy and safety of both groups. Clinical efficacy of lamotrigine treatment was assessed using changes in the Clinical Global Impression Scale for Bipolar Disorder-Modified scores during the course of the 12-week treatment A significant reduction of the Clinical Global Impression Scale for Bipolar Disorder-Modified score was observed in both groups and the effect size was large for both groups (standard, 0.75; slower, 0.71). A mixed-effect model of repeated measurement. revealed an increased rate of improvement in the standard titration group that was significant during the first 5 weeks (P<0.001) but became nonsignificant by the final 7 weeks of treatment. The statistically significant reduction in the development of rashes (P=0.005) was a major advantage for patients in the slower titration group. Although the standard titration schedule generally led to faster recovery from depressive symptoms, the slower titration schedule may be an option for patients with a high risk of rash development.ko_KR
dc.language.isoenko_KR
dc.publisherLIPPINCOTT WILLIAMS & WILKINSko_KR
dc.subjectbipolar depressionko_KR
dc.subjectlamotrigineko_KR
dc.subjectslower titrationko_KR
dc.titleFeasibility of a slower lamotrigine titration schedule for bipolar depression: a naturalistic studyko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor조수현-
dc.contributor.AlternativeAuthor장재승-
dc.contributor.AlternativeAuthor원승희-
dc.contributor.AlternativeAuthor임효덕-
dc.contributor.AlternativeAuthor하태현-
dc.contributor.AlternativeAuthor하규섭-
dc.identifier.doi10.1097/YIC.0b013e32832775fe-
dc.citation.journaltitleINTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY-
dc.description.citedreferenceKetter TA, 2008, J PSYCHIATR RES, V43, P13, DOI 10.1016/j.jpsychires.2008.02.007-
dc.description.citedreferenceCalabrese JR, 2008, BIPOLAR DISORD, V10, P323-
dc.description.citedreferenceAlvestad S, 2007, EPILEPSIA, V48, P1360, DOI 10.1111/j.1528-1167.2007.01109.x-
dc.description.citedreferenceKeck PE, 2007, CNS SPECTRUMS, V12, P1-
dc.description.citedreferenceMan CBL, 2007, EPILEPSIA, V48, P1015, DOI 10.1111/j.1528-1167.2007.01022.x-
dc.description.citedreferenceHirsch LJ, 2006, EPILEPSIA, V47, P318-
dc.description.citedreferenceOstacher MJ, 2006, J CLIN PSYCHIAT, V67, P18-
dc.description.citedreference*GLAXOSMITHKLINE, 2006, PRESCR INF LAM LAM T-
dc.description.citedreferenceKetter TA, 2005, J CLIN PSYCHIAT, V66, P642-
dc.description.citedreferenceP-Codrea S, 2005, ACTA NEUROL SCAND, V111, P191, DOI 10.1111/j.1600-0404.2005.00381.x-
dc.description.citedreferenceSilverstone PH, 2004, INT CLIN PSYCHOPHARM, V19, P113, DOI 10.1091/01.yic.0000125754.83499.55-
dc.description.citedreferenceChung WH, 2004, NATURE, V428, P486, DOI 10.1038/428486a-
dc.description.citedreferenceGueorguieva R, 2004, ARCH GEN PSYCHIAT, V61, P310-
dc.description.citedreferenceKatz MM, 2004, NEUROPSYCHOPHARMACOL, V29, P566, DOI 10.1038/sj.npp.1300341-
dc.description.citedreferenceGoodwin GM, 2004, J CLIN PSYCHIAT, V65, P432-
dc.description.citedreferenceCalabrese JR, 2003, J CLIN PSYCHIAT, V64, P1013-
dc.description.citedreferenceBowden CL, 2003, ARCH GEN PSYCHIAT, V60, P392-
dc.description.citedreferenceChoi H, 2003, EXPERT OPIN PHARMACO, V4, P243-
dc.description.citedreferenceCalabrese JR, 2002, J CLIN PSYCHIAT, V63, P1012-
dc.description.citedreferenceCalabrese JR, 2002, J CLIN PSYCHIAT, V63, P18-
dc.description.citedreferenceFrye MA, 2000, J CLIN PSYCHOPHARM, V20, P607-
dc.description.citedreferenceRzany B, 1999, LANCET, V353, P2190-
dc.description.citedreferenceCalabrese JR, 1999, J CLIN PSYCHIAT, V60, P79-
dc.description.citedreferenceMessenheimer JA, 1998, CAN J NEUROL SCI, V25, pS14-
dc.description.citedreferenceSpearing MK, 1997, PSYCHIAT RES, V73, P159-
dc.description.citedreferenceCOHEN J, 1988, STAT POWER ANAL BEHA-
dc.description.tc1-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share